JOINDER AGREEMENT

Exhibit 10.5

EXECUTION VERSION

JOINDER AGREEMENT

This Joinder Agreement is dated as of April 1, 2015 (this “Agreement”), by and among each of the financial institutions set forth on Schedule A annexed hereto (each a “New Term Loan Lender” and collectively the “New Term Loan Lenders”), Valeant Pharmaceuticals International, Inc., a corporation continued under the laws of the Province of British Columbia (“Borrower”), the undersigned subsidiaries of Borrower and Barclays Bank PLC (“Barclays”), as Administrative Agent and Collateral Agent.

RECITALS:

WHEREAS, reference is hereby made to the Third Amended and Restated Credit and Guaranty Agreement, dated as of February 13, 2012, as amended by Amendment No. 1, dated as of March 6, 2012, by Amendment No. 2, dated as of September 10, 2012, by Amendment No. 3, dated as of January 24, 2013, by Amendment No. 4, dated as of February 21, 2013, by Amendment No. 5, dated as of June 6, 2013, by Amendment No. 6, dated as of June 26, 2013, by Amendment No. 7, dated as of September 17, 2013, by Amendment No. 8, dated as of December 20, 2013, by the Successor Agent Agreement and Amendment No. 9, dated as of January 8, 2015, by Amendment No. 10, dated as of March 5, 2015, as further supplemented by the Joinder Agreement, dated as of June 14, 2012, by the Joinder Agreement, dated as of July 9, 2012, by the Joinder Agreement, dated as of September 11, 2012, by the Joinder Agreement dated as of October 2, 2012, by the Joinder Agreement, dated as of December 11, 2012, by the Joinder Agreements, each dated as of August 5, 2013, by the Joinder Agreements, each dated as of February 6, 2014, and by the Joinder Agreements, each dated as of January 22, 2015 (as it may be amended, restated, replaced, supplemented or otherwise modified from time to time, the “Credit Agreement”; the terms defined therein and not otherwise defined herein being used herein as therein defined), among Borrower, certain Subsidiaries of Borrower, as Guarantors, the Lenders party thereto from time to time, Xxxxxxx Xxxxx Lending Partners LLC (“GSLP”), X.X. Xxxxxx Securities LLC and Xxxxxx Xxxxxxx Senior Funding, Inc. (“Xxxxxx Xxxxxxx”), as Joint Lead Arrangers and Joint Bookrunners, JPMorgan Chase Bank, N.A. (“JPMorgan”) and Xxxxxx Xxxxxxx, as Co-Syndication Agents, JPMorgan, as Issuing Bank, Barclays (as successor to GSLP), as Administrative Agent and Collateral Agent, and the other Agents party thereto;

WHEREAS, subject to the terms and conditions of the Credit Agreement, Borrower may obtain New Revolving Loan Commitments and/or New Term Loan Commitments by entering into one or more Joinder Agreements with the New Term Loan Lenders; and

WHEREAS, pursuant to Section 2.25 of the Credit Agreement, the Credit Agreement may, without the consent of any other Lenders, be amended as may be necessary or appropriate, in the opinion of the Administrative Agent, to give effect to the provisions of Section 2.25 of the Credit Agreement.

NOW, THEREFORE, in consideration of the premises and agreements, provisions and covenants herein contained, the parties hereto agree as follows:

Each New Term Loan Lender (i) confirms that it has received a copy of the Credit Agreement and the other Credit Documents, together with copies of the financial statements referred to therein and such other documents and information as it has deemed appropriate to make its own credit analysis and decision to enter into this Agreement; (ii) agrees that it will, independently and without reliance upon the Administrative Agent or any other Lender or Agent and based on such documents and

information as it shall deem appropriate at the time, continue to make its own credit decisions in taking or not taking action under the Credit Agreement; (iii) appoints and authorizes Administrative Agent and each other Agent to take such action as agent on its behalf and to exercise such powers under the Credit Agreement and the other Credit Documents as are delegated to Administrative Agent or such other Agent, as the case may be, by the terms thereof, together with such powers as are reasonably incidental thereto; and (iv) agrees that it will perform in accordance with their terms all of the obligations which by the terms of the Credit Agreement are required to be performed by it as a Lender.

Each New Term Loan Lender hereby commits to provide its respective New Term Loan Commitment (each a “Series A-4 Tranche A Term Loan Commitment”) as set forth on Schedule A annexed hereto, on the terms and subject to the conditions set forth below:

1. Applicable Margin. The Applicable Margin for each New Term Loan made pursuant to this Agreement (each a “Series A-4 Tranche A Term Loan”) shall mean initially, at the Borrower’s option, (a) with respect to Series A-4 Tranche A Term Loans that are Eurodollar Rate Loans, 2.25% per annum or (b) with respect to Series A-4 Tranche A Term Loans that are Base Rate Loans, 1.25% per annum. From and after the delivery by the Borrower to the Administrative Agent of financial statements for the first full Fiscal Quarter ended after the date hereof, the Applicable Margin for each Series A-4 Tranche A Term Loan shall mean the percentages per annum set forth in the table below, based upon the Leverage Ratio of Borrower, as of the last day of the most recently ended Fiscal Quarter for which financial statements were required to have been delivered pursuant to Section 5.1(a) or (b) of the Credit Agreement:

Pricing Level		Leverage Ratio		Eurodollar Rate Loans				Base Rate Loans
I		> 4.0 to 1.0			2.25	%			1.25	%
II		£ 4.0 to 1.0 but > 3.25 to 1.0			2.00	%			1.00	%
III		£ 3.25 to 1.0			1.75	%			0.75	%

2. Principal Payments. Borrower shall make principal payments on the Series A-4 Tranche A Term Loans in installments on the dates and in the amounts equal to the percentage set forth below of an amount equal to the aggregate principal amount of the Series A-4 Tranche A Term Loans outstanding as of the applicable Delayed Draw Series A-4 Funding Date (as defined below):

Amortization Date		Series A-4 Tranche A Term Loan Installments
June 30, 2015			1.25	%
September 30, 2015			1.25	%
December 31, 2015			1.25	%
March 31, 2016			1.25	%
June 30, 2016			2.50	%
September 30, 2016			2.50	%
December 31, 2016			2.50	%
March 31, 2017			2.50	%
June 30, 2017			5.00	%
September 30, 2017			5.00	%
December 31, 2017			5.00	%
March 31, 2018			5.00	%

-2-

Amortization Date		Series A-4 Tranche A Term Loan Installments
June 30, 2018			5.00	%
September 30, 2018			5.00	%
December 31, 2018			5.00	%
March 31, 2019			5.00	%
June 30, 2019			5.00	%
September 30, 2019			5.00	%
December 31, 2019			5.00	%
March 31, 2020			5.00	%
April 1, 2020 (the “Series A-4 Tranche A Term Loan Maturity Date”)			Remaining Balance

3. Voluntary and Mandatory Prepayments. Scheduled installments of principal of the Series A-4 Tranche A Term Loans set forth above shall be reduced in connection with any voluntary or mandatory prepayments of the Series A-4 Tranche A Term Loans in accordance with Sections 2.12, 2.13, 2.14 and 2.15 of the Credit Agreement respectively.

4. Closing Fee / OID. Borrower agrees to pay on the applicable Delayed Draw Series A-4 Funding Date to Administrative Agent, for the account of each New Term Loan Lender party to this Agreement, as fee compensation for the funding of such New Term Loan Lender’s Series A-4 Tranche A Term Loans, a closing fee in an amount equal to 0.25% of the aggregate principal amount of such New Term Loan Lender’s Series A-4 Tranche A Term Loans funded as of such Delayed Draw Series A-4 Funding Date.

5. Delayed Draw Commitment Fee. Borrower agrees to pay to the Administrative Agent, for the account of each New Term Loan Lender with a Series A-4 Tranche A Term Loan Commitment, a nonrefundable commitment fee (the “Delayed Draw Commitment Fee”), which fee will commence accruing on the date hereof, and expiring on the earlier of (x) the final Delayed Draw Series A-4 Funding Date and (y) the date that is 60 days after the date hereof (the “Series A-4 Tranche A Term Loan Commitment Termination Date”) in an amount equal to 0.25% per annum (increasing to 0.50% per annum on the date that is 60 days after the date hereof) calculated based on the actual daily unfunded portion of such New Term Loan Lender’s Series A-4 Tranche A Term Loan Commitments; which Delayed Draw Commitment Fee (i) shall be payable on the earlier to occur of (a) each Delayed Draw Series A-4 Funding Date (with respect to Series A-4 Tranche A Term Loans made on such date) and (b) the Series A-4 Tranche A Term Loan Commitment Termination Date (with respect to the unfunded portion of the Series A-4 Tranche A Term Loan Commitments remaining on such date) and (ii) shall be calculated at a rate per annum, calculated on the basis of a year of 360 days and the actual number of days expired during the applicable period.

6. Proposed Borrowing.

(i) In accordance with the Credit Agreement, Borrower shall from time to time (but on no more than four (4) occasions) deliver to Administrative Agent an executed Funding Notice for Series A-4 Tranche A Term Loans (each a “Delayed Draw Funding Notice”) no later than three (3) Business Days prior to the date of the proposed borrowing (each such date, a “Delayed Draw Series A-4 Funding Date”), requesting a proposed borrowing in the aggregate principal amount of up to $1,000,000,000, but in any event not to exceed

-3-

the remaining Series A-4 Tranche A Term Loan Commitment as of such Delayed Draw Series A-4 Funding Date (collectively, the “Proposed Borrowing”), no later than the Series A-4 Tranche A Term Loan Commitment Termination Date. Upon receipt by Administrative Agent of such Delayed Draw Funding Notice, each New Term Loan Lender with a Series A-4 Tranche A Term Loan Commitment shall make its Series A-4 Tranche A Term Loans available to Administrative Agent not later than 11:00 a.m. (New York City time) on the applicable Delayed Draw Series A-4 Funding Date, by wire transfer of same day funds in Dollars at the Principal Office designated by Administrative Agent. Promptly upon receipt thereof, Administrative Agent shall make the proceeds of the applicable Series A-4 Tranche A Term Loans available to Borrower on such Delayed Draw Series A-4 Funding Date by causing an amount of same day funds in Dollars equal to the proceeds of all such loans received by Administrative Agent from New Term Loan Lenders to be credited to the account of Borrower, at the Principal Office designated by Administrative Agent or to such other account as may be designated in writing to Administrative Agent by Borrower.

(ii) Borrower may make up to four (4) borrowings each in a minimum amount of no less than $250,000,000 in respect of the Series A-4 Tranche A Term Loan Commitment, which shall be made on any Delayed Draw Series A-4 Funding Date. Each New Term Loan Lender’s Series A-4 Tranche A Term Loan Commitment shall be reduced on each Delayed Draw Series A-4 Funding Date in an amount equal to the amount of its Series A-4 Tranche A Term Loans made on such Delayed Draw Series A-4 Funding Date and any amounts borrowed and repaid or prepaid may not be re-borrowed. Each New Term Loan Lender’s Series A-4 Tranche A Term Loan Commitment shall terminate immediately and without further action on the Series A-4 Tranche A Term Loan Commitment Termination Date, regardless of whether any Series A-4 Tranche A Term Loans are made on such date.

7. Conditions to Series A-4 Tranche A Term Loan Borrowings. The obligation of each New Term Loan Lender to make a Series A-4 Tranche A Term Loan is subject to the satisfaction, or waiver in accordance with Section 10.5 of the Credit Agreement, of the following conditions precedent: (x) Administrative Agent shall have received a fully executed and delivered Delayed Draw Funding Notice; and (y) Borrower shall have delivered a certificate of a Responsible Officer in a form reasonably satisfactory to the Administrative Agent certifying that the proceeds of the Series A-4 Tranche A Term Loan shall be used solely to finance a portion of the Sun Transactions, including to consummate the Sun Convertibles Redemption (as defined below).

8. New Lenders. Each New Term Loan Lender (other than any New Term Loan Lender that, immediately prior to the execution of this Agreement, is a “Lender” under the Credit Agreement) acknowledges and agrees that upon its execution of this Agreement its Series A-4 Tranche A Term Loan Commitments shall be effective and that such New Term Loan Lender shall become a “Lender” under, and for all purposes of, the Credit Agreement and the other Credit Documents, and shall be subject to and bound by the terms thereof, and shall perform all the obligations of and shall have all rights of a Lender thereunder.

9. Credit Agreement Governs. The Series A-4 Tranche A Term Loan Commitments and Series A-4 Tranche A Term Loans made pursuant thereto shall be subject to the provisions of the Credit Agreement and the other Credit Documents, except as set forth in this Agreement, and shall constitute “Tranche A Term Loan Exposure” and “Tranche A Term Loans”, respectively, thereunder.

-4-

10. Borrower’s Certifications. By its execution of this Agreement, the undersigned officer, to the best of his or her knowledge, and Borrower hereby certify that:

i. The representations and warranties set forth in Section 4.1(a) of the Credit Agreement (solely with respect to due organization), Section 4.1(b) of the Credit Agreement (solely with respect to this Agreement), Section 4.3 of the Credit Agreement (solely with respect to this Agreement), Section 4.4(a)(ii) of the Credit Agreement (solely with respect to this Agreement), 4.4(b) of the Credit Agreement with respect to material debt agreements (solely with respect to this Agreement); Section 4.6 of the Credit Agreement (solely with respect to this Agreement), Section 4.15 of the Credit Agreement (solely with respect to regulation under the Investment Company Act of 1940), Section 4.16 of the Credit Agreement (solely with respect to this Agreement); Section 4.20 of the Credit Agreement; Section 4.23 of the Credit Agreement (solely with respect to the PATRIOT Act and the U.S. Foreign Corrupt Practices Act of 1977) and Section 4.25 of the Credit Agreement are true and correct in all material respects on and as of the date hereof to the same extent as though made on and as of the date hereof, except to the extent such representations and warranties specifically relate to an earlier date, in which case such representations and warranties were true and correct in all material respects on and as of such earlier date; and

ii. Borrower has performed in all material respects all agreements and satisfied all conditions which the Credit Agreement provides shall be performed or satisfied by it on or before the date hereof in connection with the Proposed Borrowing.

11. Borrower Covenants. By its execution of this Agreement, Borrower hereby covenants that:

i. Borrower shall deliver or cause to be delivered, on or before the date hereof (the “Closing Date”), the following legal opinions and documents: originally executed copies of the favorable written opinions of (a) Skadden, Arps, Slate, Xxxxxxx & Xxxx LLP, U.S. counsel and special France counsel to the Credit Parties, (b) Chancery Xxxxxxxx, special Barbados counsel to the Credit Parties, (c) Norton Xxxx Xxxxxxxxx Canada LLP, special Canada counsel to the Credit Parties, (d) Xxxxx & XxXxxxxx, special Luxembourg counsel to the Credit Parties, (e) Xxxxxxx Xxxx & Xxxxxxx Limited, special Bermuda counsel to the Credit Parties, (f) Xxxxxx Xxx, special Ireland counsel to the Credit Parties, (g) Xxxxxxx LLP, special Maryland counsel to the Credit Parties, (h) Souza, Cescon, Barrieu & Xxxxxx Advogados, special Brazil counsel to the Credit Parties, (i) Xxxxxx Xxxxxxx Xxxxxxxxx Xxxxxxxxx sp.k., special Poland counsel to the Credit Parties, (j) Xxxx Xxxxxx Sutkiene, special Lithuania counsel to the Credit Parties, (k) White & Case LLP, special France counsel to the Administrative Agent, (l) Xxxxx & Xxxxx LLP, special Netherlands counsel to the Administrative Agent, (m) Rajah & Xxxx LLP, special Singapore counsel to the Credit Parties, (n) Stamford Law Corporation, special Singapore counsel to the Administrative Agent , (o) Fluxmans Inc., special South Africa counsel to the Credit Parties and (p) White & Case LLP, special United Kingdom counsel to the Administrative Agent, together with all other legal opinions and other documents reasonably requested by Administrative Agent in connection with this Agreement.

ii. Notwithstanding anything to the contrary contained in this Agreement or the other Credit Documents, the parties hereto acknowledge and agree that the delivery

-5-

of any document or instrument and the taking of any action, in each case set forth on Schedule B hereto shall not be a condition precedent to the Closing Date but shall be required to be satisfied after the Closing Date in accordance with Schedule B hereto.

12. Sun Acquisition. The Sun Acquisition shall have been consummated or shall be consummated substantially simultaneously with the signing of this Agreement.

13. Use of Proceeds. The proceeds of any Series A-4 Tranche A Term Loans on each Delayed Draw Series A-4 Funding Date shall be used to finance a portion of the Sun Transactions, including the payment of any cash consideration necessary upon the conversion of the Sun Convertible Notes (the “Sun Convertibles Redemption”).

14. Eligible Assignee. By its execution of this Agreement, each New Term Loan Lender (other than any New Term Loan Lender that, immediately prior to the execution of this Agreement, is a “Lender” under the Credit Agreement) represents and warrants that it is an Eligible Assignee.

15. Notice. For purposes of the Credit Agreement, the initial notice address of each New Term Loan Lender shall be as set forth below its signature below.

16. Non-U.S. Lenders. For each New Term Loan Lender that is a Non-U.S. Lender, delivered herewith to Administrative Agent are such forms, certificates or other evidence with respect to United States federal income tax withholding matters as such New Term Loan Lender may be required to deliver to Administrative Agent pursuant to subsection 2.20(d) of the Credit Agreement.

17. Recordation of the New Loans. Upon the funding of any Series A-4 Tranche A Term Loans on the applicable Delayed Draw Series A-4 Funding Date, Administrative Agent will record such Series A-4 Tranche A Term Loans made by New Term Loan Lenders pursuant hereto in the Register.

18. Reaffirmation.

i. Each Credit Party hereby expressly acknowledges the terms of this Agreement and reaffirms, as of the date hereof, the covenants and agreements contained in each Credit Document to which it is a party (including the covenants and agreements contained in Amendment No. 10 whether or not such Credit Party was party thereto), including, in each case, such covenants and agreements as in effect immediately after giving effect to this Agreement and the transactions contemplated hereby.

ii. Each Credit Party, by its signature below, hereby affirms and confirms (a) its obligations under each of the Credit Documents to which it is a party (including the obligations under Amendment No. 10 whether or not such Credit Party was party thereto), and (b) the pledge of and/or grant of a security interest or hypothec in its assets as Collateral to secure such Obligations, all as provided in the Collateral Documents as originally executed, and acknowledges and agrees that such guarantee, pledge and/or grant continue in full force and effect in respect of, and to secure, such Obligations under the Credit Agreement and the other Credit Documents.

-6-

ii. Each Credit Party acknowledges and agrees that each of the Credit Documents in existence as of the date hereof shall be henceforth read and construed in accordance with and so as to give full force and effect to the ratifications, confirmations, acknowledgements and agreements made herein.

19. Amendment, Modification and Waiver. This Agreement may not be amended, modified or waived except by an instrument or instruments in writing signed and delivered on behalf of each of the parties hereto.

20. Entire Agreement. This Agreement, the Credit Agreement and the other Credit Documents constitute the entire agreement among the parties with respect to the subject matter hereof and thereof and supersede all other prior agreements and understandings, both written and verbal, among the parties or any of them with respect to the subject matter hereof. It is understood and agreed that each reference in each Credit Document to the Credit Agreement, whether direct or indirect, shall hereafter be deemed to be a reference to the Credit Agreement as amended and supplemented hereby and that this Agreement is a Credit Document.

21. GOVERNING LAW. THIS AGREEMENT AND THE RIGHTS AND OBLIGATIONS OF THE PARTIES HEREUNDER SHALL BE GOVERNED BY, AND SHALL BE CONSTRUED AND ENFORCED IN ACCORDANCE WITH THE LAWS OF THE STATE OF NEW YORK.

22. Severability. Any term or provision of this Agreement which is invalid or unenforceable in any jurisdiction shall, as to that jurisdiction, be ineffective to the extent of such invalidity or unenforceability without rendering invalid or unenforceable the remaining terms and provisions of this Agreement or affecting the validity or enforceability of any of the terms or provisions of this Agreement in any other jurisdiction. If any provision of this Agreement is so broad as to be unenforceable, the provision shall be interpreted to be only so broad as would be enforceable.

23. Counterparts. This Agreement may be executed in counterparts, each of which shall be deemed to be an original, but all of which shall constitute one and the same agreement.

24. Termination. The Series A-4 Tranche A Term Loan Commitments shall automatically terminate on the Series A-4 Tranche A Term Loan Commitment Termination Date.

[Remainder of page intentionally left blank]

-7-

IN WITNESS WHEREOF, each of the undersigned has caused its duly authorized officer to execute and deliver this Agreement as of the date first written above.

DEUTSCHE BANK AG NEW YORK BRANCH, as a “New Term Loan Lender”
By:		/s/ Xxxxxxx Xxxxxxx
Name:		Xxxxxxx Xxxxxxx
Title:		Vice President
DEUTSCHE BANK AG NEW YORK BRANCH, as a “New Term Loan Lender”
By:		/s/ Xxxx X. Xxxxxxxx
Name:		Xxxx X. Xxxxxxxx
Title:		Director

Notice Address:

Attention:

Telephone:

Facsimile:

[Signature Page to Joinder Agreement]

VALEANT PHARMACEUTICALS INTERNATIONAL, INC.
By:		/s/ Xxxxx X. XxXxxxx
Name:		Xxxxx X. XxXxxxx
Title:		Senior Vice President and Treasurer
VALEANT PHARMACEUTICALS INTERNATIONAL
By:		/s/ Xxxxx X. XxXxxxx
Name:		Xxxxx X. XxXxxxx
Title:		Senior Vice President and Treasurer
BAUSCH & LOMB INCORPORATED
By:		/s/ Xxxxx X. XxXxxxx
Name:		Xxxxx X. XxXxxxx
Title:		Senior Vice President and Treasurer
BAUSCH & LOMB HOLDINGS INCORPORATED
By:		/s/ Xxxxx X. XxXxxxx
Name:		Xxxxx X. XxXxxxx
Title:		Vice President and Treasurer
SOLTA MEDICAL, INC.
By:		/s/ Xxxxx X. XxXxxxx
Name:		Xxxxx X. XxXxxxx
Title:		Senior Vice President and Treasurer

[Signature Page to Joinder Agreement]

ATON PHARMA, INC.
By:		/s/ Xxxxx X. XxXxxxx
Name:		Xxxxx X. XxXxxxx
Title:		Senior Vice President and Treasurer
XXXXX LABORATORIES, LTD.
By:		/s/ Xxxxx X. XxXxxxx
Name:		Xxxxx X. XxXxxxx
Title:		Senior Vice President and Treasurer
DOW PHARMACEUTICAL SCIENCES, INC.
By:		/s/ Xxxxx X. XxXxxxx
Name:		Xxxxx X. XxXxxxx
Title:		Senior Vice President and Treasurer

[Signature Page to Joinder Agreement]

OBAGI MEDICAL PRODUCTS, INC.
By:		/s/ Xxxxx X. XxXxxxx
Name:		Xxxxx X. XxXxxxx
Title:		Treasurer
OMP, INC.
By:		/s/ Xxxxx X. XxXxxxx
Name:		Xxxxx X. XxXxxxx
Title:		Treasurer
ONPHARMA INC.
By:		/s/ Xxxxx X. XxXxxxx
Name:		Xxxxx X. XxXxxxx
Title:		Treasurer

[Signature Page to Joinder Agreement]

Signed by
Valeant Holdco 2 Pty Ltd (ACN 154 341 367)
in accordance with section 127 of the Corporations Xxx 0000 by two directors:
/s/ Xxxxxx X Xxxx-Onn				/s/ Xxxxx X. XxXxxxx
Signature of director				Signature of director
Xxxxxx X. Xxxx-Onn				Xxxxx X. XxXxxxx
Name of director (please print)				Name of director (please print)
Signed by
Wirra Holdings Pty Limited (ACN 122 216 577) in accordance with section 127 of the Corporations Xxx 0000 by two directors:
/s/ Xxxxxx X Xxxx-Onn				/s/ Xxxxx X. XxXxxxx
Signature of director				Signature of director
Xxxxxx X. Xxxx-Onn				Xxxxx X. XxXxxxx
Name of director (please print)				Name of director (please print)
Signed by
Wirra Operations Pty Limited (ACN 122 250 088) in accordance with section 127 of the Corporations Xxx 0000 by two directors:
/s/ Xxxxxx X Xxxx-Onn				/s/ Xxxxx X. XxXxxxx
Signature of director				Signature of director
Xxxxxx X. Xxxx-Onn				Xxxxx X. XxXxxxx
Name of director (please print)				Name of director (please print)

[Signature Page to Joinder Agreement]

Signed by
iNova Pharmaceuticals (Australia) Pty Limited (ACN 000 222 408)
in accordance with section 127 of the Corporations Xxx 0000 by two directors:
/s/ Xxxxxx X Xxxx-Onn				/s/ Xxxxx X. XxXxxxx
Signature of director				Signature of director
Xxxxxx X. Xxxx-Onn				Xxxxx X. XxXxxxx
Name of director (please print)				Name of director (please print)
Signed by
Wirra IP Pty Limited (ACN 000 000 000)
in accordance with section 127 of the Corporations Xxx 0000 by two directors:
/s/ Xxxxxx X Xxxx-Onn				/s/ Xxxxx X. XxXxxxx
Signature of director				Signature of director
Xxxxxx X. Xxxx-Onn				Xxxxx X. XxXxxxx
Name of director (please print)				Name of director (please print)
Signed by
iNova Sub Pty Limited (ACN 134 398 815)
in accordance with section 127 of the Corporations Xxx 0000 by two directors:
/s/ Xxxxxx X Xxxx-Onn				/s/ Xxxxx X. XxXxxxx
Signature of director				Signature of director
Xxxxxx X. Xxxx-Onn				Xxxxx X. XxXxxxx
Name of director (please print)				Name of director (please print)

[Signature Page to Joinder Agreement]

Signed by
Valeant Pharmaceuticals Australasia Pty Limited (ACN 001 083 352)
in accordance with section 127 of the Corporations Xxx 0000 by a director and secretary/director:
/s/ Xxxxxx X Xxxx-Onn				/s/ Xxxxx X. XxXxxxx
Signature of director				Signature of director/secretary
Xxxxxx X. Xxxx-Onn				Xxxxx X. XxXxxxx
Name of director (please print)				Name of director/secretary (please print)
Signed by
DermaTech Pty Limited (ACN 000 000 000)
in accordance with section 127 of the Corporations Xxx 0000 by a director and secretary/director:
/s/ Xxxxxx X Xxxx-Onn				/s/ Xxxxxx X. Xxxxxxxx
Signature of director				Signature of director/secretary
Xxxxxx X. Xxxx-Onn				Xxxxxx X. Xxxxxxxx
Name of director (please print)				Name of director/secretary (please print)

[Signature Page to Joinder Agreement]

Signed by
Private Formula International Holdings Pty Ltd (ACN 095 450 918)
in accordance with section 127 of the Corporations Xxx 0000 by a director and secretary/director:
/s/ Xxxxxx X Xxxx-Onn				/s/ Xxxxxx X. Xxxxxxxx
Signature of director				Signature of director/secretary
Xxxxxx X. Xxxx-Onn				Xxxxxx X. Xxxxxxxx
Name of director (please print)				Name of director/secretary (please print)
Signed by
Private Formula International Pty Ltd (ACN 095 451 442)
in accordance with section 127 of the Corporations Xxx 0000 by a director and secretary/director:
/s/ Xxxxxx X Xxxx-Onn				/s/ Xxxxxx X. Xxxxxxxx
Signature of director				Signature of director/secretary
Xxxxxx X. Xxxx-Onn				Xxxxxx X. Xxxxxxxx
Name of director (please print)				Name of director/secretary (please print)

[Signature Page to Joinder Agreement]

Signed by
Ganehill Pty Ltd (ACN 065 261 538)
in accordance with section 127 of the Corporations Xxx 0000 by a director and secretary/director:
/s/ Xxxxxx X Xxxx-Onn				/s/ Xxxxxx X. Xxxxxxxx
Signature of director				Signature of director/secretary
Xxxxxx X. Xxxx-Onn				Xxxxxx X. Xxxxxxxx
Name of director (please print)				Name of director/secretary (please print)

[Signature Page to Joinder Agreement]

Signed by
Bausch & Lomb (Australia) Pty Ltd (ACN: 000 650 251)
in accordance with section 127 of the Corporations Xxx 0000 by a director and secretary/director:
/s/ Xxxxx X. XxXxxxx				/s/ Xxxx Xxxx
Signature of director				Signature of director/secretary
Xxxxx XxXxxxx				Xxxx Xxxx
Name of director (please print)				Name of director/secretary (please print)

[Signature Page to Joinder Agreement]

HYTHE PROPERTY INCORPORATED
By:		/s/ Xxxxxxxx Xxxxxx
Name:		Xxxxxxxx Xxxxxx
Title:		Manager and Assistant Secretary

[Signature Page to Joinder Agreement]

VALEANT INTERNATIONAL BERMUDA
By:		/s/ Xxxxxx Xxxxxxx
Name:		Xxxxxx Xxxxxxx
Title:		Director
VALEANT PHARMACEUTICALS NOMINEE BERMUDA
By:		/s/ Xxxxx XxXxxxx
Name:		Xxxxx XxXxxxx
Title:		President and Assistant Secretary

[Signature Page to Joinder Agreement]

PROBIÓTICA LABORATÓRIOS LTDA.
By:		/s/ Xxxxxxx Xxxx Xxxxxxx
Name:		Xxxxxxx Xxxx Xxxxxxx
Title:		Officer
By:		/s/ Xxxxxxxxx Xxxxxxx
Name:		Xxxxxxxxx Xxxxxxx
Title:		Officer

[Signature Page to Joinder Agreement]

IOLAB CORPORATION
By:		/s/ Xxxxx X. XxXxxxx
Name:		Xxxxx X. XxXxxxx
Title:		Treasurer
TECHNOLAS PERFECT VISION, INC.
By:		/s/ Xxxxx X. XxXxxxx
Name:		Xxxxx X. XxXxxxx
Title:		Senior Vice President and Treasurer
BAUSCH & LOMB PHARMA HOLDINGS CORP.
By:		/s/ Xxxxx X. XxXxxxx
Name:		Xxxxx X. XxXxxxx
Title:		Senior Vice President and Treasurer
BAUSCH & LOMB CHINA, INC.
By:		/s/ Xxxxx X. XxXxxxx
Name:		Xxxxx X. XxXxxxx
Title:		Senior Vice President and Treasurer
BAUSCH & LOMB SOUTH ASIA, INC.
By:		/s/ Xxxxx X. XxXxxxx
Name:		Xxxxx X. XxXxxxx
Title:		Senior Vice President and Treasurer
BAUSCH & LOMB TECHNOLOGY CORPORATION
By:		/s/ Xxxxx X. XxXxxxx
Name:		Xxxxx X. XxXxxxx
Title:		Treasurer

[Signature Page to Joinder Agreement]

RHC HOLDINGS, INC.
By:		/s/ Xxxxx X. XxXxxxx
Name:		Xxxxx X. XxXxxxx
Title:		Senior Vice President and Treasurer
SIGHT SAVERS, INC.
By:		/s/ Xxxxx X. XxXxxxx
Name:		Xxxxx X. XxXxxxx
Title:		Senior Vice President and Treasurer
BAUSCH & LOMB INTERNATIONAL, INC.
By:		/s/ Xxxxx X. XxXxxxx
Name:		Xxxxx X. XxXxxxx
Title:		Senior Vice President and Treasurer
BAUSCH & LOMB REALTY CORPORATION.
By:		/s/ Xxxxx X. XxXxxxx
Name:		Xxxxx X. XxXxxxx
Title:		Vice President and Treasurer
ISTA PHARMACEUTICALS, LLC
By:		/s/ Xxxxx X. XxXxxxx
Name:		Xxxxx X. XxXxxxx
Title:		Senior Vice President and Treasurer
VRX HOLDCO, INC.
By:		/s/ Xxxxx X. XxXxxxx
Name:		Xxxxx X. XxXxxxx
Title:		Chief Financial Officer and Treasurer

[Signature Page to Joinder Agreement]

VALEANT CANADA GP LIMITED
By:		/s/ Xxxxxx X. Xxxxxxxx
Name:		Xxxxxx X. Xxxxxxxx
Title:		Executive Vice President and Chief Financial Officer
VALEANT CANADA S.E.C./VALEANT CANADA LP
By:		/s/ Xxxxxx X. Xxxxxxxx
Name:		Xxxxxx X. Xxxxxxxx
Title:		Executive Vice President and Chief Financial Officer
V-BAC HOLDING CORP.
By:		/s/ Xxxxxx X. Xxxx-Onn
Name:		Xxxxxx X. Xxxx-Onn
Title:		Vice President

[Signature Page to Joinder Agreement]

MEDICIS PHARMACEUTICAL CORPORATION
By:		/s/ Xxxxx X. XxXxxxx
Name:		Xxxxx X. XxXxxxx
Title:		Senior Vice President and Treasurer
OCEANSIDE PHARMACEUTICALS, INC.
By:		/s/ Xxxxxx X. Xxxxxxxx
Name:		Xxxxxx X. Xxxxxxxx
Title:		Chief Financial Officer and Treasurer
XX. XXXXXX’X PRIVATE FORMULA INTERNATIONAL, INC.
By:		/s/ Xxxxx X. XxXxxxx
Name:		Xxxxx X. XxXxxxx
Title:		Senior Vice President and Treasurer
PRINCETON PHARMA HOLDINGS, LLC
By:		/s/ Xxxxx X. XxXxxxx
Name:		Xxxxx X. XxXxxxx
Title:		Senior Vice President and Treasurer
PRIVATE FORMULA CORP.
By:		/s/ Xxxxx X. XxXxxxx
Name:		Xxxxx X. XxXxxxx
Title:		Senior Vice President and Treasurer
XXXXXX SKIN CARE LABORATORIES, INC.
By:		/s/ Xxxxx X. XxXxxxx
Name:		Xxxxx X. XxXxxxx
Title:		Senior Vice President and Treasurer

[Signature Page to Joinder Agreement]

VALEANT BIOMEDICALS, INC.
By:		/s/ Xxxxxx X. Xxxxxxxx
Name:		Xxxxxx X. Xxxxxxxx
Title:		Chief Financial Officer and Treasurer
VALEANT PHARMACEUTICALS NORTH AMERICA LLC
By:		/s/ Xxxxx X. XxXxxxx
Name:		Xxxxx X. XxXxxxx
Title:		Senior Vice President and Treasurer
BIOVAIL AMERICAS CORP.
By:		/s/ Xxxxxx X. Xxxxxxxx
Name:		Xxxxxx X. Xxxxxxxx
Title:		Chief Financial Officer and Treasurer
ORAPHARMA, INC.
By:		/s/ Xxxxx X. XxXxxxx
Name:		Xxxxx X. XxXxxxx
Title:		Senior Vice President and Treasurer
ORAPHARMA TOPCO HOLDINGS, INC.
By:		/s/ Xxxxx X. XxXxxxx
Name:		Xxxxx X. XxXxxxx
Title:		Senior Vice President and Treasurer
PRESTWICK PHARMACEUTICALS, INC.
By:		/s/ Xxxxxx X. Xxxxxxxx
Name:		Xxxxxx X. Xxxxxxxx
Title:		Chief Financial Officer and Treasurer

[Signature Page to Joinder Agreement]

BIOVAIL INTERNATIONAL S.Á.X.X.
By:		/s/ Xxxxxxxx Xx Xxxxxx
Name:		Xxxxxxxx Xx Xxxxxx
Title:		Manager
VALEANT PHARMACEUTICALS LUXEMBOURG S.Á.X.X.
By:		/s/ Xxxxxxxx Xx Xxxxxx
Name:		Xxxxxxxx Xx Xxxxxx
Title:		Manager
VALEANT INTERNATIONAL LUXEMBOURG S.Á.X.X.
By:		/s/ Xxxxxxxx Xx Xxxxxx
Name:		Xxxxxxxx Xx Xxxxxx
Title:		Manager
BAUSCH & LOMB LUXEMBOURG S.Á.X.X.
By:		/s/ Xxxxxxxx Xx Xxxxxx
Name:		Xxxxxxxx Xx Xxxxxx
Title:		Manager

[Signature Page to Joinder Agreement]

LABORATOIRE XXXXXXX S.A.S.
By:		/s/ Xxxxx X. XxXxxxx
Name:		Xxxxx X. XxXxxxx
Title:		General Manager
BAUSCH & LOMB FRANCE S.A.S.
By:		/s/ Xxxxx X. XxXxxxx
Name:		Xxxxx X. XxXxxxx
Title:		General Manager
BCF S.A.S.
By:		/s/ Xxxxx X. XxXxxxx
Name:		Xxxxx X. XxXxxxx
Title:		General Manager
XXXXXXX OPSIA S.A.S.
By:		/s/ Xxxxx X. XxXxxxx
Name:		Xxxxx X. XxXxxxx
Title:		General Manager

[Signature Page to Joinder Agreement]

VALEANT PHARMA HUNGARY LLC
By:		/s/ Xxxxxx Xxxxxx
Name:		Xxxxxx Xxxxxx
Title:		Managing Director
VALEANT PHARMA HUNGARY LLC
By:		/s/ Xxxxxx Xxxxx
Name:		Xxxxxx Xxxxx
Title:		Finance Director

[Signature Page to Joinder Agreement]

VALEANT PHARMACEUTICALS IRELAND
By:		/s/ Xxxxxx Xxxxxxx
Name:		Xxxxxx Xxxxxxx
Title:		Director
VALEANT HOLDINGS IRELAND
By:		/s/ Xxxxxx Xxxxxxx
Name:		Xxxxxx Xxxxxxx
Title:		Director

[Signature Page to Joinder Agreement]

B.L.J. COMPANY, LTD.
By:		/s/ Xxx Xxxxxxx
Name:		Xxx Xxxxxxx
Title:		Representative Director and President

[Signature Page to Joinder Agreement]

AB SANITAS
By:		/s/ Xxxxx Xxxxxxxx
Name:		Xxxxx Xxxxxxxx
Title:		General Manager

[Signature Page to Joinder Agreement]

UCYCLYD PHARMA, INC.
By:		/s/ Xxxxx X. XxXxxxx
Name:		Xxxxx X. XxXxxxx
Title:		Senior Vice President and Treasurer

[Signature Page to Joinder Agreement]

VALEANT EUROPE B.V.
By:		/s/ Xxxxxx Xxxxxx
Name:		Xxxxxx Xxxxxx
Title:		Attorney-in-Fact
BAUSCH & LOMB B.V.
By:		/s/ Xxxxxx Xxxxxx
Name:		Xxxxxx Xxxxxx
Title:		Attorney-in-Fact
BAUSCH & LOMB OPS B.V.
By:		/s/ Xxxxxx Xxxxxx
Name:		Xxxxxx Xxxxxx
Title:		Attorney-in-Fact

[Signature Page to Joinder Agreement]

PRZEDSIĘBIORSTWO FARMACEUTYCZNE JELFA S.A.
By:		/s/ Xxxxxx Xxxxxxxxx
Name:		Xxxxxx Xxxxxxxxx
Title:		Attorney-in-Fact
VALEANT SP.Z O. O.
By:		/s/ Xxxxxx Xxxxxxxxx
Name:		Xxxxxx Xxxxxxxxx
Title:		Attorney-in-Fact
VP VALEANT SP. Z O.O.SP.J.
By:		/s/ Xxxxxx Xxxxxxxxx
Name:		Xxxxxx Xxxxxxxxx
Title:		Attorney-in-Fact
VALEANT SPÓŁKA Z OGRANICZONĄ ODPOWIEDZIALNOŚCIĄ SP.J.
By:		/s/ Xxxxxx Xxxxxxxxx
Name:		Xxxxxx Xxxxxxxxx
Title:		Attorney-in-Fact

[Signature Page to Joinder Agreement]

PHARMASWISS D.O.O., BEOGRAD
By:		/s/ Xxxxx Xxxxxxx
Name:		Xxxxx Xxxxxxx
Title:		General Manager
		(corporate stamp)

[Signature Page to Joinder Agreement]

PHARMASWISS D.O.O.,
By:		/s/ Senahil Asanagić
Name:		Senahil Asanagić
Title:		Director

[Signature Page to Joinder Agreement]

INOVA PHARMACEUTICALS PROPRIETARY LIMITED
By:		/s/ Xxxxxx X. Xxxxxxxx
Name:		Xxxxxx X. Xxxxxxxx
Title:		Director

[Signature Page to Joinder Agreement]

PHARMASWISS SA
By:		/s/ Matthias Courvoisier
Name:		Matthias Courvoisier
Title:		Director

[Signature Page to Joinder Agreement]

Executed by BAUSCH & LOMB U.K. LIMITED, acting by:
/s/ Xxxxx X. XxXxxxx
Director
Name of director: Xxxxx X. LaGorgain the presence of:
/s/ Xxx Xxxxxxx
Name of witness: Xxx Xxxxxxx
Address:		000 Xxxxxxxx Xxxxxxxxx Xxxx.
		Xxxxxxxxxxx, Xxx Xxxxxx 00000 X.X.X.
Occupation: Finance

[Signature Page to Joinder Agreement]

BAUSCH & LOMB IOM S.P.A.
By:		/s/ Xxxxx X. XxXxxxx
Name:		Xxxxx X. XxXxxxx
Title:		Director

[Signature Page to Joinder Agreement]

SIGNED for and on behalf

)

of VALEANT PHARMACEUTICALS NEW ZEALAND LIMITED

)  )

/s/ Xxxxxx Xxxxxxxx

/s/ Xxxxxx X. Xxxx-Onn

Name:

Xxxxxx Xxxxxxxx

Name:

Xxxxxx X. Xxxx-Onn

Title:

Director

Title:

Director

[Signature Page to Joinder Agreement]

INOVA PHARMACEUTICALS (SINGAPORE) PTE LIMITED
By:		/s/ Xxxxxx Xxxxxxxx
Name:		Xxxxxx Xxxxxxxx
Title:		Director

[Signature Page to Joinder Agreement]

Consented to by:
BARCLAYS BANK PLC
As Administrative Agent and Collateral Agent
By:		/s/ Xxxxx Xxxxxx
		Authorized Signatory

[Signature Page to Joinder Agreement]

SCHEDULE A

TO JOINDER AGREEMENT

Name of Lender		Type of Commitment		Amount
DEUTSCHE BANK AG NEW YORK BRANCH		Series A-4 Tranche A Term Loan Commitment		$	1,000,000,000
Total:				$	1,000,000,000

SCHEDULE B

TO JOINDER AGREEMENT

POST-CLOSING MATTERS

Hungary Post-Closing Matters

		ITEM		TIME LIMIT1
1.		Execution and registration of the Pledge on All Assets Agreement		May 31, 2015
2.		Execution and filing of the Quota Pledge Agreement		May 31, 2015
3.		Execution and registration of, and delivering related notification under, the Pledge Over Bank Accounts Agreement		May 31, 2015
4.		Execution and filing of the Trademark Pledge Agreement		May 31, 2015

¹  The Administrative Agent shall have sole and absolute discretion to agree to a longer period.

Italy Post-Closing Matters

		ITEM		TIME LIMIT2
1.		Confirmation Agreement of the Italian law Share Pledge relating to Bausch & Lomb IOM S.p.A.		April 8, 2015
2.		Confirmation Agreement (post syndication) of the Italian law Share Pledge relating to Bausch & Lomb IOM S.p.A.		June 8, 2015

²  The Administrative Agent shall have sole and absolute discretion to agree to a longer period.

Lithuania Post-Closing Matters

		ITEM		TIME LIMIT3
1.		Execution and notarization of Agreement On Amendment Of Maximum Company Mortgage Agreement Identification Code 20120130056526		April 10, 2015
2.		Execution and notarization of Agreement On Amendment Of Maximum Pledge Agreement Identification Code 20220130056528		April 10, 2015
3.		Execution and notarization of Agreement On Amendment Of Contractual Maximum Pledge Bond No 01220120007548		April 10, 2015
4.		Xxxx Xxxxxx Sutkiene, special Lithuania counsel to the Credit Parties, shall deliver or cause to be delivered to the Administrative Agent an executed copy of its customary opinion in form and substance reasonably satisfactory to the Administrative Agent.		April 13, 2015

³  The Administrative Agent shall have sole and absolute discretion to agree to a longer period.

The Netherlands Post-Closing Matters

		ITEM		TIME LIMIT4
1.		Execution and notarisation of the Second Ranking Security Agreement Pledge Of Shares between Valeant Holdings Ireland as Security Provider, Barclays Bank PLC as Collateral Agent and Bausch+Lomb OPS B.V. as Company		April 8, 2015
2.		Execution and notarisation of the Security Agreement Pledge Of Shares between Przedsiębiorstwo Farmaceutyczne Jelfa S.A., Valeant Pharmaceuticals International, Inc. and Pharmaswiss S.A., as Security Providers, Barclays Bank PLC as Collateral Agent and Valeant Europe B.V. as Company		April 8, 2015
3.		Xxxxx & Xxxxx LLP, special Netherlands counsel to the Administrative Agent, shall deliver or cause to be delivered to the Administrative Agent an executed copy of its customary opinion in form and substance reasonably satisfactory to the Administrative Agent.		April 8, 2015

⁴  The Administrative Agent shall have sole and absolute discretion to agree to a longer period.

Poland Post-Closing Matters

		ITEM		TIME LIMIT5
1.		The amendment agreement to the agreement for registered pledge over collection of assets of Przedsiębiorstwo Farmaceutyczne JELFA S.A. dated 17 September 2013 (as amended) to be entered into between Przedsiębiorstwo Farmaceutyczne JELFA S.A. as pledgor and Barclays as pledgee		April 15, 2015
2.		The amendment agreement to the agreement for registered pledge and financial pledge over shares in “Emo-Farm” sp. z o.o. dated 17 September 2013 (as amended) to be entered into between Przedsiębiorstwo Farmaceutyczne JELFA S.A. as pledgor and Barclays as pledgee		April 15, 2015
3.		The amendment agreement to the agreement for financial pledges over bank accounts of Przedsiębiorstwo Farmaceutyczne JELFA S.A. dated 17 September 2013 (as amended) to be entered into between Przedsiębiorstwo Farmaceutyczne JELFA S.A. as pledgor and Barclays as pledgee		April 15, 2015
4.		The amendment agreement to the agreement for registered pledges over bank accounts of Przedsiębiorstwo Farmaceutyczne JELFA S.A. dated 17 September 2013 (as amended) to be entered into between Przedsiębiorstwo Farmaceutyczne JELFA S.A. as pledgor and Barclays as pledgee		April 15, 2015
5.		The amendment agreement to the agreement for registered pledge and financial pledge over shares in “Valeant” sp. z o.o. dated 17 September 2013 (as amended) to be entered into between Valeant Europe BV as pledgor and Barclays as pledgee		April 15, 2015
6.		The amendment agreement to the agreement for registered and financial pledges over investment certificates (A and B series) issued by Ipopema 00 Xxxxxxx Xxxxxxxxxxxx Xxxxxxxxx Xxxxxxx Xxxxxxxxxxxxxx dated 17 September 2013 (as amended) to be entered into between Valeant Europe BV as pledgor and Barclays as pledgee		April 15, 2015
7.		The amendment agreement to the agreement for registered pledges over bank accounts of Valeant sp. z o.o. dated 24 September 2013 (as amended) to be entered into between Valeant sp. z o.o. as pledgor and Barclays as pledgee		April 15, 2015

⁵  The Administrative Agent shall have sole and absolute discretion to agree to a longer period.

8.		The amendment agreement to the agreement for financial pledges over bank accounts of Valeant sp. z o.o. dated 24 September 2013 (as amended) to be entered into between Valeant sp. z o.o. as pledgor and Barclays as pledgee		April 15, 2015
9.		The amendment agreement to the agreement for registered pledge over collection of assets of Valeant sp. z o.o. dated 24 September 2013 (as amended) to be entered into between Valeant sp. z o.o. as pledgor and Barclays as pledgee		April 15, 2015
10.		The amendment agreement to the agreement for registered pledge over bank account of VP Valeant sp. z o.o. sp.j. dated 24 September 2013 (as amended) to be entered into between VP Valeant sp. z o.o. sp.j. as pledgor and Barclays as pledgee		April 15, 2015
11.		The amendment agreement to the agreement for financial pledge over bank account of VP Valeant sp. z o.o. sp.j. dated 24 September 2013 (as amended) to be entered into between VP Valeant sp. z o.o. sp.j. as pledgor and Barclays as pledgee		April 15, 2015
12.		The amendment agreement to the agreement for registered pledge over collection of assets of VP Valeant sp. z o.o. sp.j. dated 24 September 2013 (as amended) to be entered into between VP Valeant sp. z o.o. sp.j. as pledgor and Barclays as pledgee		April 15, 2015
13.		The amendment agreement to the agreement for registered pledge and financial pledge over shares in Przedsiębiorstwo Farmaceutyczne JELFA S.A. dated 21 October 2013 (as amended) to be entered into between Sanitas AB as pledgor and Barclays as pledgee		April 15, 2015
14.		The amendment agreement to the agreement for registered and financial pledges over investment certificates (C series) issued by Ipopema 00 Xxxxxxx Xxxxxxxxxxxx Xxxxxxxxx Xxxxxxx Xxxxxxxxxxxxxx dated 21 October 2013 (as amended) to be entered into between Valeant Europe BV as pledgor and Barclays as pledgee		April 15, 2015
15.		The amendment agreement to the agreement for registered pledges over protection rights over trademarks of Valeant sp. z o.o. sp.j. dated 22 November 2013 (as amended) to be entered into between Valeant sp. z o.o. sp.j. as pledgor and Barclays as pledgee		April 15, 2015

16.		The amendment agreement to the agreement for registered pledges over bank accounts of Valeant sp. z o.o. sp.j. dated 22 November 2013 (as amended) to be entered into between Valeant sp. z o.o. sp.j. as pledgor and Barclays as pledgee		April 15, 2015
17.		The amendment agreement to the agreement for financial pledges over bank accounts of Valeant sp. z o.o. sp.j. dated 22 November 2013 (as amended) to be entered into between Valeant sp. z o.o. sp.j. as pledgor and Barclays as pledgee		April 15, 2015
18.		The amendment agreement to the agreement for registered pledge over collection of assets of Valeant sp. z o.o. sp.j. dated 22 November 2013 (as amended) to be entered into between Valeant sp. z o.o. sp.j. as pledgor and Barclays as pledgee		April 15, 2015
19.		The amendment agreement to the agreement for registered and financial pledges over investment certificates (D series) issued by Ipopema 00 Xxxxxxx Xxxxxxxxxxxx Xxxxxxxxx Xxxxxxx Xxxxxxxxxxxxxx dated 3 February 2014 (as amended) to be entered into between Valeant Europe BV as pledgor and Barclays as pledgee		April 15, 2015
20.		The amendment agreement to the agreement for registered and financial pledges over investment certificates (E series) issued by Ipopema 00 Xxxxxxx Xxxxxxxxxxxx Xxxxxxxxx Xxxxxxx Xxxxxxxxxxxxxx dated 22 August 2014 (as amended) to be entered into between Valeant Europe BV as pledgor and Barclays as pledgee		April 15, 2015
21.		The agreement for registered and financial pledges over investment certificates to be issued by Ipopema 00 Xxxxxxx Xxxxxxxxxxxx Xxxxxxxxx Xxxxxxx Xxxxxxxxxxxxxx to be entered into between Valeant Europe BV as pledgor and Barclays as pledgee		April 15, 2015
22.		The agreement for registered pledge and the financial pledge over shares in the increased share capital of Valeant sp. z o.o. to be entered into between Valeant Europe B.V. as pledgor and Barclays as pledgee		April 15, 2015
23.		The statement on submission to enforcement of Sanitas AB		April 15, 2015
24.		The statement on submission to enforcement of Valeant Europe BV		April 15, 2015

25.		The statement on submission to enforcement of Przedsiębiorstwo Farmaceutyczne JELFA S.A		April 15, 2015
26.		The statement on submission to enforcement of Valeant sp. z o.o		April 15, 2015
27.		The statement on submission to enforcement of VP Valeant sp. z o.o. sp.j.		April 15, 2015
28.		the statement on submission to enforcement of Valeant sp. z o.o. sp.j.		April 15, 2015
29.		the statement on amendment of the existing mortgage to be made by Przedsiębiorstwo Farmaceutyczne JELFA S.A		April 15, 2015
30.		Squire Xxxxxx Xxxxx Xxxxxxxxx Xxxxxxxxx xx.k. special Poland counsel to the Credit Parties, shall deliver or cause to be delivered to the Admistrative Agent an executed copy of its customary opinion in form and substance reasonably satisfactory to the Administrative Agent.		April 15, 2015
31.		White & Case LLP, special counsel to the Administrative Agent, shall deliver or cause to be delivered to the Administrative Agent an executed copy of its customary opinion in a form and substance reasonably satisfactory to the Administrative Agent		Xxxxx 00, 0000

Xxxxxxxx Post-Closing Matters

		ITEM		TIME LIMIT6
1.		Execution and registration of the Pledge Agreement between Pharmaswiss SA, as Pledgor, and Barclays Bank PLC, as Pledgee and Collateral Agent		April 8, 2015
2.		Notification of the Share Pledge by Pharmaswiss SA to the management of Pharmaswiss d.o.o. (to be sent via registered mail)		April 8, 2015

⁶  The Administrative Agent shall have sole and absolute discretion to agree to a longer period.

South Africa Post-Closing Matters

		ITEM		TIME LIMIT1
1.		Appointment letter of processional trust company as Manager for Debt Guarantor		April 15, 2015
3.		Memorandum of Incorporation of the Debt Guarantor		April 15, 2015
4.		Trust Deed of Owner Trustee		April 15, 2015
5.		Debt Guarantor Management Agreement		April 15, 2015
6.		Debt Guarantee		April 15, 2015
7.		Counter-Indemnity Agreement		April 15, 2015
8.		Exchange Control Approval		April 15, 2015
9.		Bond cancellation in relation to existing Notarial General Bond		April 15, 2015
10.		Registration of new general notarial bond in favour of security SPV		May 29, 2015
11.		Fluxmans Inc., special South Africa counsel to the Credit Parties, shall deliver or cause to be delivered to the Administrative Agent an executed copy of its customary opinion in form and substance reasonably satisfactory to the Administrative Agent.		April 15, 2015
12.		White and Case, special South Africa counsel to the Administrative Agent, shall deliver or cause to be delivered to the Administrative Agent an executed copy of its customary opinion in form and substance reasonably satisfactory to the Administrative Agent.		April 15, 2015

⁷  The Administrative Agent shall have sole and absolute discretion to agree to a longer period.